
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
According to a recently completed analysis from the Tufts Center for the Study of Drug Development, drug development for rare diseases presents scientific and operational challenges that will accelerate the adoption of new development strategies and operating models.
For more on their findings, click






